CLRBClinical Trials•globenewswire•
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
Sentiment:Positive (70)
Summary
(NASDAQ:CLRB) Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 11, 2025 by globenewswire